EdgarLookup

Aurinia Pharmaceuticals Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Aurinia Pharmaceuticals Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $73.47M Nov 4, 2025
Q2 2025 Jun 30, 2025 $70.01M Jul 31, 2025
Q1 2025 Mar 31, 2025 $62.47M May 12, 2025
Q3 2025 Sep 30, 2024 $67.77M Nov 4, 2025
Q2 2025 Jun 30, 2024 $57.19M Jul 31, 2025
Q1 2025 Mar 31, 2024 $50.30M May 12, 2025
Q3 2024 Sep 30, 2023 $54.52M Nov 7, 2024
Q2 2024 Jun 30, 2023 $41.49M Aug 1, 2024
Q1 2024 Mar 31, 2023 $34.41M May 2, 2024
Q3 2023 Sep 30, 2022 $55.78M Nov 2, 2023
Q2 2023 Jun 30, 2022 $28.19M Aug 3, 2023
Q1 2023 Mar 31, 2022 $21.63M May 4, 2023
Q3 2022 Sep 30, 2021 $14.67M Nov 3, 2022
Q2 2022 Jun 30, 2021 $6.62M Aug 4, 2022
Q1 2022 Mar 31, 2021 $914.0K May 10, 2022
Q3 2021 Sep 30, 2020 $29.0K Nov 3, 2021
Q2 2021 Jun 30, 2020 $29.0K Aug 5, 2021
Q1 2021 Mar 31, 2020 $30.0K May 6, 2021

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $31.55M Nov 4, 2025
Q2 2025 Jun 30, 2025 $21.51M Jul 31, 2025
Q3 2025 Jun 30, 2025 $21.51M Nov 4, 2025
Q3 2025 Mar 31, 2025 $23.34M Nov 4, 2025
Q1 2025 Mar 31, 2025 $23.34M May 12, 2025
Q2 2025 Mar 31, 2025 $23.34M Jul 31, 2025
Q3 2025 Sep 30, 2024 $14.35M Nov 4, 2025
Q2 2025 Jun 30, 2024 $722.0K Jul 31, 2025
Q3 2025 Jun 30, 2024 $722.0K Nov 4, 2025
Q2 2025 Mar 31, 2024 ($10.75M) Jul 31, 2025
Q1 2025 Mar 31, 2024 ($10.75M) May 12, 2025
Q3 2025 Mar 31, 2024 ($10.75M) Nov 4, 2025
Q3 2024 Sep 30, 2023 ($13.45M) Nov 7, 2024
Q2 2024 Jun 30, 2023 ($11.49M) Aug 1, 2024
Q1 2024 Mar 31, 2023 ($26.21M) May 2, 2024
Q3 2023 Sep 30, 2022 ($8.99M) Nov 2, 2023
Q2 2023 Jun 30, 2022 ($35.52M) Aug 3, 2023
Q1 2023 Mar 31, 2022 ($37.63M) May 4, 2023
Q3 2022 Sep 30, 2021 ($50.26M) Nov 3, 2022
Q2 2022 Jun 30, 2021 ($47.01M) Aug 4, 2022

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $29.75M Nov 4, 2025
Q2 2025 Jun 30, 2025 $20.08M Jul 31, 2025
Q1 2025 Mar 31, 2025 $21.85M May 12, 2025
Q3 2025 Sep 30, 2024 $11.75M Nov 4, 2025
Q2 2025 Jun 30, 2024 ($1.51M) Jul 31, 2025
Q1 2025 Mar 31, 2024 ($13.25M) May 12, 2025
Q3 2024 Sep 30, 2023 ($16.26M) Nov 7, 2024
Q2 2024 Jun 30, 2023 ($16.17M) Aug 1, 2024
Q1 2024 Mar 31, 2023 ($29.58M) May 2, 2024
Q3 2023 Sep 30, 2022 ($9.50M) Nov 2, 2023
Q2 2023 Jun 30, 2022 ($35.99M) Aug 3, 2023
Q1 2023 Mar 31, 2022 ($37.88M) May 4, 2023
Q3 2022 Sep 30, 2021 ($50.35M) Nov 3, 2022
Q2 2022 Jun 30, 2021 ($47.13M) Aug 4, 2022
Q1 2022 Mar 31, 2021 ($50.54M) May 10, 2022
Q3 2021 Sep 30, 2020 ($42.32M) Nov 3, 2021
Q2 2021 Jun 30, 2020 ($26.86M) Aug 5, 2021
Q1 2021 Mar 31, 2020 ($27.06M) May 6, 2021